Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of Favezelimab (MK-4280) Alone and with Pembrolizumab ± Chemotherapy or Lenvatinib in Advanced Solid Tumors
jRCT2080223914Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- May 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab, favezelimab and lenvatinib in Nonhematologic neoplasms and cancer (4 arms), sponsored by Merck & Co. Started May 2018; status: completed.
02
Drugs
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on jRCT2080223914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223914.